Status:
RECRUITING
Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer
Lead Sponsor:
Jon Unosson
Conditions:
Pancreas Cancer
Pancreas Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Lymph node metastases are a strong prognostic predictor for pancreatic cancer. Para-aortic lymph nodes (PALN) are the final nodes for periampullary cancers before the cancer cells enter the systemic l...
Detailed Description
Lymph node metastases are a strong prognostic predictor for pancreatic cancer. Para-aortic lymph nodes (PALN) (No. 16 nodes) are the final nodes for periampullary cancers before the cancer cells enter...
Eligibility Criteria
Inclusion
- Resectable suspected periampullary cancer (requiring duodenopancreatectomy) (NCCN guidelines 2020)
- Borderline resectable periampullary cancer (requiring duodenopancreatectomy) (NCCN guidelines 2020)
- Age \>18 years
- Written patient consent
Exclusion
- Contraindication for a radical resection procedure
- Unresectable tumor (NCCN guidelines 2020) or metastatic disease (lgll station 16 not included)
- Mental or organic disorders which could interfere with giving informed consent or receiving treatments
Key Trial Info
Start Date :
September 5 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 5 2028
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06065891
Start Date
September 5 2023
End Date
September 5 2028
Last Update
October 4 2023
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Odense University Hospital
Odense, Denmark
2
Sahlgrenska university hospital
Gothenburg, Sweden
3
Linköping University Hospital
Linköping, Sweden
4
Skåne University Hospital
Lund, Sweden